Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Enterprise Value (2021 - 2025)

Amylyx Pharmaceuticals has reported Enterprise Value over the past 5 years, most recently at -$317.0 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$317.0 million for Q4 2025, down 79.59% from a year ago — trailing twelve months through Dec 2025 was -$317.0 million (down 79.59% YoY), and the annual figure for FY2025 was -$317.0 million, down 79.59%.
  • Enterprise Value for Q4 2025 was -$317.0 million at Amylyx Pharmaceuticals, up from -$344.0 million in the prior quarter.
  • Over the last five years, Enterprise Value for AMLX hit a ceiling of -$96.1 million in Q4 2021 and a floor of -$373.3 million in Q1 2024.
  • Median Enterprise Value over the past 5 years was -$309.8 million (2024), compared with a mean of -$272.8 million.
  • Biggest five-year swings in Enterprise Value: crashed 260.96% in 2022 and later skyrocketed 52.47% in 2024.
  • Amylyx Pharmaceuticals' Enterprise Value stood at -$96.1 million in 2021, then crashed by 260.96% to -$346.9 million in 2022, then dropped by 7.04% to -$371.4 million in 2023, then skyrocketed by 52.47% to -$176.5 million in 2024, then tumbled by 79.59% to -$317.0 million in 2025.
  • The last three reported values for Enterprise Value were -$317.0 million (Q4 2025), -$344.0 million (Q3 2025), and -$180.8 million (Q2 2025) per Business Quant data.